Last reviewed · How we verify
Ranibizumab + laser
Ranibizumab + laser is a VEGF inhibitor (monoclonal antibody fragment) Small molecule drug developed by Jaeb Center for Health Research. It is currently in Phase 3 development for Proliferative diabetic retinopathy (PDR), Diabetic macular edema (DME) with retinal thickening. Also known as: Lucentis, anti-VEGF drug.
Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, combined with laser photocoagulation to seal leaking vessels in the retina.
Ranibizumab, an inhibitor of vascular endothelial growth factor A, is used in combination with laser treatment to manage various eye conditions, including macular edema and retinal vein occlusion. The combination of ranibizumab and laser photocoagulation has been studied in clinical trials for its efficacy and safety in treating these conditions.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ranibizumab + laser |
|---|---|
| Also known as | Lucentis, anti-VEGF drug |
| Sponsor | Jaeb Center for Health Research |
| Drug class | VEGF inhibitor (monoclonal antibody fragment) |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Ranibizumab is a monoclonal antibody fragment that inhibits VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. When combined with laser therapy, which thermally destroys abnormal retinal tissue and seals leaking vessels, the dual approach addresses both the molecular drivers of disease and the structural vascular abnormalities. This combination is used to treat proliferative diabetic retinopathy and other retinal vascular disorders.
Approved indications
- Proliferative diabetic retinopathy (PDR)
- Diabetic macular edema (DME) with retinal thickening
Common side effects
- Conjunctival hemorrhage
- Eye pain or discomfort
- Floaters
- Intraocular inflammation
- Endophthalmitis (rare)
Key clinical trials
- Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns (PHASE3)
- Combination of Ranibizumab and Targeted Laser Photocoagulation (PHASE3)
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (PHASE4)
- Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging (PHASE1, PHASE2)
- Rainbow Extension Study (PHASE3)
- Focal Laser Single Intravitreal Ranibizumab Retinal Artery Macroaneurysm.
- Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity (PHASE3)
- Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ranibizumab + laser CI brief — competitive landscape report
- Ranibizumab + laser updates RSS · CI watch RSS
- Jaeb Center for Health Research portfolio CI
Frequently asked questions about Ranibizumab + laser
What is Ranibizumab + laser?
How does Ranibizumab + laser work?
What is Ranibizumab + laser used for?
Who makes Ranibizumab + laser?
Is Ranibizumab + laser also known as anything else?
What drug class is Ranibizumab + laser in?
What development phase is Ranibizumab + laser in?
What are the side effects of Ranibizumab + laser?
What does Ranibizumab + laser target?
Related
- Drug class: All VEGF inhibitor (monoclonal antibody fragment) drugs
- Target: All drugs targeting VEGF-A
- Manufacturer: Jaeb Center for Health Research — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Proliferative diabetic retinopathy (PDR)
- Indication: Drugs for Diabetic macular edema (DME) with retinal thickening
- Also known as: Lucentis, anti-VEGF drug
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing